Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex.

Epilepsia - 1 Oct 2016

Hess Evan J, Moody Kirsten A, Geffrey Alexandra L, Pollack Sarah F, Skirvin Lauren A, Bruno Patricia L, Paolini Jan L, Thiele Elizabeth A

Abstract excerpt

OBJECTIVE: Tuberous sclerosis complex (TSC) is an autosomal-dominant genetic disorder with highly variable expression. The most common neurologic manifestation of TSC is epilepsy, which affects approximately 85% of patients, 63% of whom develop treatment-resistant epilepsy. Herein, we evaluate the efficacy, safety, and tolerability of cannabidiol (CBD), a nonpsychoactive compound derived from the marijuana plant,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticonvulsants
Share to Calcium-Binding Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Child, Preschool

Share to Drug Resistant Epilepsy

Share to Follow-Up Studies

Share to Treatment Outcome

Share to Tuberous Sclerosis

Share to Young Adult

Source

Identifiers

PMID: 27696387
DOI: 10.1111/epi.13499

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex.PMID 27696387Read ↗

Modulating Neural Excitability in Epilepsy: A Systems-Level Perspective on Cannabinoid–Terpene SignalingSemantic proximity Read ↗

Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing StudiesSemantic proximity Read ↗

Topical Review: Intractable Seizures in Tuberous Sclerosis Complex: From Molecular Pathogenesis to the Rationale for TreatmentSemantic proximity Read ↗

Cannabidiol in Neurology: Current Insights and Translational PerspectivesSemantic proximity Read ↗

CBD can be combined with additional cannabinoids for optimal seizure reduction and requires GPR55 for its anticonvulsant effectsSemantic proximity Read ↗

Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot studySemantic proximity Read ↗

Potential clinical benefits of CBD-rich Cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysisSemantic proximity Read ↗

Characterization and Anticonvulsant Effects of a Colombian Cannabis sativa Extract: A Preclinical Study in Murine Models of EpilepsySemantic proximity Read ↗

Epilepsy in Tuberous Sclerosis: Phenotypes, Mechanisms, and Treatments.Semantic proximity Read ↗

Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical ResearchSemantic proximity Read ↗

Colombian consensus of treatment with pure cannabidiol (CBD) in PsychiatrySemantic proximity Read ↗

Response to cannabidiol in epilepsy of infancy with migrating focal seizures associated with KCNT1 mutations: An open-label, prospective, interventional study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.